Literature DB >> 30913985

Process optimization and protein engineering mitigated manufacturing challenges of a monoclonal antibody with liquid-liquid phase separation issue by disrupting inter-molecule electrostatic interactions.

Qun Du1, Melissa Damschroder1, Timothy M Pabst2, Alan K Hunter2, William K Wang2, Haibin Luo2.   

Abstract

We report a case study in which liquid-liquid phase separation (LLPS) negatively impacted the downstream manufacturability of a therapeutic mAb. Process parameter optimization partially mitigated the LLPS, but limitations remained for large-scale manufacturing. Electrostatic interaction driven self-associations and the resulting formation of high-order complexes are established critical properties that led to LLPS. Through chain swapping substitutions with a well-behaved antibody and subsequent study of their solution behaviors, we found the self-association interactions between the light chains (LCs) of this mAb are responsible for the LLPS behavior. With the aid of in silico homology modeling and charged-patch analysis, seven charged residues in the LC complementarity-determining regions (CDRs) were selected for mutagenesis, then evaluated for self-association and LLPS properties. Two charged residues in the light chain (K30 and D50) were identified as the most significant to the LLPS behaviors and to the antigen-binding affinity. Four adjacent charged residues in the light chain (E49, K52, R53, and R92) also contributed to self-association, and thus to LLPS. Molecular engineering substitution of these charged residues with a neutral or oppositely-charged residue disrupted the electrostatic interactions. A double-mutation in CDR2 and CDR3 resulted in a variant that retained antigen-binding affinity and eliminated LLPS. This study demonstrates the critical nature of surface charged resides on LLPS, and highlights the applied power of in silico protein design when applied to improving physiochemical characteristics of therapeutic antibodies. Our study indicates that in silico design and effective protein engineering may be useful in the development of mAbs that encounter similar LLPS issues.

Entities:  

Keywords:  AC-SINS; DLS; Liquid-liquid phase separation; antibody engineering; homology modeling; interaction parameter (); manufacturing process; monoclonal antibody; reversible self-association

Mesh:

Substances:

Year:  2019        PMID: 30913985      PMCID: PMC6601553          DOI: 10.1080/19420862.2019.1599634

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  27 in total

Review 1.  Close-range electrostatic interactions in proteins.

Authors:  Sandeep Kumar; Ruth Nussinov
Journal:  Chembiochem       Date:  2002-07-02       Impact factor: 3.164

2.  Coarse-grained modeling of the self-association of therapeutic monoclonal antibodies.

Authors:  Anuj Chaudhri; Isidro E Zarraga; Tim J Kamerzell; J Paul Brandt; Thomas W Patapoff; Steven J Shire; Gregory A Voth
Journal:  J Phys Chem B       Date:  2012-07-06       Impact factor: 2.991

3.  Charge heterogeneity of monoclonal antibodies by multiplexed imaged capillary isoelectric focusing immunoassay with chemiluminescence detection.

Authors:  David A Michels; Andrea W Tu; Will McElroy; David Voehringer; Oscar Salas-Solano
Journal:  Anal Chem       Date:  2012-06-05       Impact factor: 6.986

4.  Liquid-liquid phase separation of a monoclonal antibody and nonmonotonic influence of Hofmeister anions.

Authors:  Bruce D Mason; Jian Zhang-van Enk; Le Zhang; Richard L Remmele; Jifeng Zhang
Journal:  Biophys J       Date:  2010-12-01       Impact factor: 4.033

Review 5.  Downstream processing of monoclonal antibodies--application of platform approaches.

Authors:  Abhinav A Shukla; Brian Hubbard; Tim Tressel; Sam Guhan; Duncan Low
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-10-13       Impact factor: 3.205

6.  Phase behavior of an intact monoclonal antibody.

Authors:  Tangir Ahamed; Beatriz N A Esteban; Marcel Ottens; Gijs W K van Dedem; Luuk A M van der Wielen; Marc A T Bisschops; Albert Lee; Christine Pham; Jörg Thömmes
Journal:  Biophys J       Date:  2007-04-20       Impact factor: 4.033

7.  Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity.

Authors:  Sonoko Kanai; Jun Liu; Thomas W Patapoff; Steven J Shire
Journal:  J Pharm Sci       Date:  2008-10       Impact factor: 3.534

Review 8.  The effects of shear flow on protein structure and function.

Authors:  Innocent B Bekard; Peter Asimakis; Joseph Bertolini; Dave E Dunstan
Journal:  Biopolymers       Date:  2011-05-04       Impact factor: 2.505

9.  Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis.

Authors:  R Blake Pepinsky; Laura Silvian; Steven A Berkowitz; Graham Farrington; Alexey Lugovskoy; Lee Walus; John Eldredge; Allan Capili; Sha Mi; Christilyn Graff; Ellen Garber
Journal:  Protein Sci       Date:  2010-05       Impact factor: 6.725

10.  Phase separation in solutions of monoclonal antibodies and the effect of human serum albumin.

Authors:  Ying Wang; Aleksey Lomakin; Ramil F Latypov; George B Benedek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-15       Impact factor: 11.205

View more
  5 in total

1.  Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Authors:  Robert J Benschop; Chi-Kin Chow; Yu Tian; James Nelson; Barbra Barmettler; Shane Atwell; David Clawson; Qing Chai; Bryan Jones; Jon Fitchett; Stacy Torgerson; Yan Ji; Holly Bina; Ningjie Hu; Mahmoud Ghanem; Joseph Manetta; Victor J Wroblewski; Jirong Lu; Barrett W Allan
Journal:  MAbs       Date:  2019-06-10       Impact factor: 5.857

2.  Utility of High Resolution 2D NMR Fingerprinting in Assessing Viscosity of Therapeutic Monoclonal Antibodies.

Authors:  Subhabrata Majumder; Deep S Bhattacharya; Alex Langford; Arun Alphonse Ignatius
Journal:  Pharm Res       Date:  2022-02-16       Impact factor: 4.580

3.  Mitigation of liquid-liquid phase separation of a monoclonal antibody by mutations of negative charges on the Fab surface.

Authors:  Tatsuji Matsuoka; Ryuki Miyauchi; Nobumi Nagaoka; Jun Hasegawa
Journal:  PLoS One       Date:  2020-10-30       Impact factor: 3.240

Review 4.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

5.  Stability of a high-concentration monoclonal antibody solution produced by liquid-liquid phase separation.

Authors:  Jack E Bramham; Stephanie A Davies; Adrian Podmore; Alexander P Golovanov
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.